Epigamia to build larger plant as factories near full capacity amid value-added dairy boom

Verlinvest-backed Epigamia plans a new manufacturing plant, funded internally, as its 8 factories run at 85% utilization. The move follows 50%+ revenue growth to ₹180 crore in FY24, while competition intensifies with Milky Mist's IPO, Amul investments and new-age rivals.

— Source publishedMon, 6 Jul, 2026, 11:02 IST·First seen Mon, 6 Jul, 2026, 11:05 IST·Source Mint

What happened

Verlinvest-backed dairy brand Epigamia plans a larger manufacturing plant as existing factories near full capacity, funded internally without new fundraise.

Key facts

  • 85% capacity utilization
  • 8 factories
  • $80 million raised
  • ₹760 crore
  • ₹1,250 crore valuation
  • 50%+ revenue growth
  • ₹180 crore FY24 revenue
  • ₹17.4 crore net loss
  • 150+ cities
  • 50-50 distribution mix

Why this matters

Verlinvest-backed Epigamia's capacity build and category-wide consolidation (Milky Mist IPO, Amul investments) mark an active window for partnership, co-manufacturing, or roll-up positioning in value-added dairy.

What to watch

  • New plant capex size, location and commissioning timeline
  • Milky Mist IPO pricing and post-listing expansion aggression
  • Amul value-added dairy launches and pricing moves
  • Epigamia FY25 revenue run-rate and utilization at existing 8 plants
  • Any external fundraise or Verlinvest stake action
  • Lock plant site and phase capex to stay internally funded; avoid debt while competitors raise IPO/PE money
  • Accelerate high-margin SKU expansion (protein, plant-based, functional) to justify premium and differentiate from Amul mass play
  • Deepen cold-chain and modern-trade + quick-commerce distribution before rivals lock shelf space
  • Verlinvest may signal follow-on capital or an eventual exit/IPO path given Milky Mist benchmark

Also reported by